Patents by Inventor Ales Medek
Ales Medek has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11951212Abstract: The present invention features compositions comprising a plurality of therapeutic agents wherein the presence of one therapeutic agent enhances the properties of at least one other therapeutic agent. In one embodiment, the therapeutic agents are cystic fibrosis transmembrane conductance regulators (CFTR) such as a CFTR corrector or CFTR potentiator for the treatment of CFTR mediated diseases such as cystic fibrosis. Methods and kits thereof are also disclosed.Type: GrantFiled: March 17, 2021Date of Patent: April 9, 2024Assignee: Vertex Pharmaceuticals IncorporatedInventors: Brian Dean Phenix, Laurent Jean-Claude Bagnol, Geoffrey Glen Brodeur, Sachin Chandran, Eleni Dokou, Lori Ann Ferris, Dragutin Knezic, Katie Lynn McCarty, Ales Medek, Sara A. Waggener
-
Patent number: 11884672Abstract: The disclosure provides compounds useful for treating alpha-1 antitrypsin deficiency (AATD), according to formula (I): tautomers thereof, pharmaceutically acceptable salts of the compounds, pharmaceutically acceptable salts of the tautomers, deuterated derivatives of the compounds, deuterated derivatives of the tautomers, and deuterated derivatives of the salts, solid forms of those compounds and processes for making those compounds.Type: GrantFiled: May 13, 2020Date of Patent: January 30, 2024Assignee: Vertex Pharmaceuticals IncorporatedInventors: Upul Keerthi Bandarage, Cavan McKeon Bligh, Diane Boucher, Michael John Boyd, Michael Aaron Brodney, Michael Philip Clark, Veronique Damagnez, Lev Tyler Dewey Fanning, Robert Francis Fimognari, Gabrielle Simone Fleming, Kevin James Gagnon, Pedro Manuel Garcia Barrantes, Robert Daniel Giacometti, Simon Giroux, Ronald Lee Grey, Jr., Samantha Guido, Amy Beth Hall, Sarah Carol Hood, Dennis James Hurley, Mac Arthur Johnson, Jr., Peter Jones, Sarathy Kesavan, Mei-Hsiu Lai, Siying Liu, Adam Looker, Brad Maxwell, John Patrick Maxwell, Ales Medek, Philippe Marcel Nuhant, Kirk Alan Overhoff, Setu Roday, Stefanie Roeper, Steven M. Ronkin, Rupa Sawant, Yi Shi, Muna Shrestha, Marisa Sposato, Kathy Stavropoulos, Rebecca Jane Swett, Timothy Lewis Tapley, Qing Tang, Stephen Thomson, Jinwang Xu, Mariam Zaky, Kevin Michael Cottrell
-
Patent number: 11873300Abstract: Crystalline forms of Compound I: pharmaceutically acceptable salts thereof, and solvates and hydrates thereof are disclosed. Pharmaceutical compositions comprising the same, methods of treating cystic fibrosis using the same, and methods for making the same are also disclosed.Type: GrantFiled: August 13, 2020Date of Patent: January 16, 2024Assignee: Vertex Pharmaceuticals IncorporatedInventors: Yi Shi, Kevin J. Gagnon, Jicong Li, Jennifer Lu, Ales Medek, Muna Shrestha, Michael Waldo, Beili Zhang, Carl L. Zwicker, Corey Don Anderson, Jeremy J. Clemens, Thomas Cleveland, Timothy Richard Coon, Bryan Frieman, Peter Grootenhuis, Sara Sabina Hadida Ruah, Jason McCartney, Mark Thomas Miller, Prasuna Paraselli, Fabrice Pierre, Sara E. Swift, Jinglan Zhou
-
Publication number: 20240002386Abstract: Solid forms of 4-(5-(4-fluorophenyl)-6-(tetrahydro-2H-pyran-4-yl)-1,5-dihydropyrrolo[2,3-f]indazol-7-yl)benzoic acid (Compound 1) capable of modulating alpha-1 antitrypsin (AAT) activity and methods of treating alpha-1 antitrypsin deficiency (AATD) by administering one or more such forms, and methods of using and preparing the same for treatment of alpha-1 antitrypsin deficiency (AATD).Type: ApplicationFiled: November 17, 2021Publication date: January 4, 2024Inventors: Yi SHI, Mei-Hsiu LAI, Ales MEDEK, Kan-Nian HU, Zhengtian SONG, Elisa A. TORRICO GUZMAN, Kathleen Paige SOKOLOWSKY, Simon GIROUX, Siying LIU, Kirk Alan OVERHOFF, Setu RODAY, Rupa SAWANT, Marisa SPOSATO
-
Publication number: 20230271945Abstract: The disclosure provides at least one entity chosen from compounds of formula (I), solid state forms of the same, compositions comprising the same, and methods of using the same, including use in treating focal segmental glomerulosclerosis (FSGS) and/or non-diabetic kidney disease (NDKD).Type: ApplicationFiled: February 7, 2023Publication date: August 31, 2023Inventors: Jingrong CAO, Jon H. COME, Leslie A. DAKIN, Francois DENIS, Warren A. DORSCH, Anne FORTIER, Martine HAMEL, Elaine B. KRUEGER, Brian LEDFORD, Suganthini S. NANTHAKUMAR, Olivier NICOLAS, Camil SAYEGH, Timothy J. SENTER, Tiansheng WANG, Michael BRODNEY, Kan-Nian HU, Peter ROSE, Kevin GAGNON, Yi SHI, Muna SHRESTHA, Ales MEDEK, Faith WITKOS
-
Publication number: 20230265080Abstract: Novel compounds, compositions, and methods of using and preparing the same, which may be useful for treating alpha-1 antitrypsin deficiency (AATD).Type: ApplicationFiled: February 9, 2023Publication date: August 24, 2023Inventors: Upul Keerthi BANDARAGE, Cavan McKeon BLIGH, Michael John BOYD, Diane M. BOUCHER, Michael Aaron BRODNEY, Veronique DAMAGNEZ, Lev Tyler DEWEY FANNING, Mary Elizabeth ECCLES, Robert Francis FIMOGNARI, JR., Kevin James GAGNON, Pedro M. GARCIA BARRANTES, Simon GIROUX, Ronald Lee GREY, JR., Amy Beth HALL, Sarah Carol HOOD, Dennis James HURLEY, Joshua Kennedy HUSSEY, Mac Arthur JOHNSON, JR., Peter JONES, Sarathy KESAVAN, Adam LOOKER, Brad D. MAXWELL, John Patrick MAXWELL, Ales MEDEK, Mettachit NAVAMAL, Philippe Marcel NUHANT, Setu RODAY, Stefanie ROEPER, Rupa SAWANT, Yi SHI, Rebecca Jane SWETT, Qing TANG, Timothy Lewis TAPLEY, Stephen A. THOMSON, Michael WALDO, Jinwang XU, Kevin Michael COTTRELL
-
Publication number: 20230250087Abstract: The disclosure provides novel solid state forms of Compound I selected from ethanol solvate Form A, ethanol solvate Form B, citric acid cocrystal Form A, and Form B, compositions comprising the same, and methods of making and using the same, including use in treating APOL1 mediated kidney disease. (I).Type: ApplicationFiled: June 11, 2021Publication date: August 10, 2023Inventors: Kevin James GAGNON, Jicong LI, Ales MEDEK, Jack Raphael MINCHOM, Yi SHI, Muna SHRESTHA, Faith WITKOS
-
Publication number: 20230203000Abstract: The disclosure provides at least one compound, tautomer, deuterated derivative, or pharmaceutically acceptable salt chosen from compounds of Formula I, tautomers thereof, deuterated derivatives of those compounds or tautomers, and pharmaceutically acceptable salts of any of the foregoing, compositions comprising the same, and methods of using the same, including uses in treating APOL1-mediated diseases, including pancreatic cancer, focal segmental glomerulosclerosis (FSGS), and/or non-diabetic kidney disease (NDKD).Type: ApplicationFiled: November 29, 2022Publication date: June 29, 2023Inventors: Leslie A. DAKIN, Michael A. BRODNEY, Kevin B. DANIEL, Elena DOLGIKH, Pedro M. GARCIA BARRANTES, Ales MEDEK, Jessica H. OLSEN, Timothy J. SENTER, Akira J. SHIMIZU, Steven D. STONE, Charlene TSAY
-
Publication number: 20230119114Abstract: The disclosure provides novel solid state forms of Compound I chosen from Compound I Phosphate Salt Hydrate Form A, Compound I free form Monohydrate, Compound I Phosphate Salt Methanol Solvate, and Compound I Phosphate Salt MEK Solvate, compositions comprising the same, and methods of making and using the same, including uses in treating APOL1 mediated disease (such as, e.g., APOL1 mediated kidney disease). Also provided herein are novel solid state forms of Compound II chosen from Compound II Phosphate Salt Hemihydrate Form A, Compound II free form Hemihydrate Form A, and Compound II free form Form C, compositions comprising the same, and methods of making and using the same, including uses in treating APOL1 mediated disease (such as, e.g., APOL1 mediated kidney disease).Type: ApplicationFiled: August 25, 2022Publication date: April 20, 2023Inventors: Kevin Brett DANIEL, Lori Ann FERRIS, Kevin James GAGNON, Michael David JUDELSON, Mei-Hsiu LAI, Courtney K. MAGUIRE, Ales MEDEK, Andrey PERESYPKIN, Peter Jamison ROSE, Yi SHI, Charlene TSAY
-
Patent number: 11623924Abstract: Novel compounds, compositions, and methods of using and preparing the same, which may be useful for treating alpha-1 antitrypsin deficiency (AATD).Type: GrantFiled: October 4, 2019Date of Patent: April 11, 2023Assignee: Vertex Pharmaceuticals IncorporatedInventors: Upul Keerthi Bandarage, Cavan McKeon Bligh, Michael John Boyd, Diane M. Boucher, Michael Aaron Brodney, Veronique Damagnez, Lev Tyler Dewey Fanning, Mary Elizabeth Eccles, Robert Francis Fimognari, Jr., Kevin James Gagnon, Pedro M. Garcia Barrantes, Simon Giroux, Ronald Lee Grey, Jr., Amy Beth Hall, Sarah Carol Hood, Dennis James Hurley, Joshua Kennedy Hussey, Mac Arthur Johnson, Jr., Peter Jones, Sarathy Kesavan, Adam Looker, Brad D. Maxwell, John Patrick Maxwell, Ales Medek, Mettachit Navamal, Philippe Marcel Nuhant, Setu Roday, Stefanie Roeper, Rupa Sawant, Yi Shi, Rebecca Jane Swett, Qing Tang, Timothy Lewis Tapley, Stephen A. Thomson, Michael Waldo, Jinwang Xu, Kevin Michael Cottrell
-
Patent number: 11618746Abstract: The disclosure provides a compound of Formula (I), including deuterated derivatives, pharmaceutically acceptable salts, and solvates thereof, solid state forms of those compounds, compositions comprising those compounds and solid forms, and methods of using the same, including use in treating focal segmental glomerulosclerosis (FSGS) and/or non-diabetic kidney disease (NDKD).Type: GrantFiled: December 17, 2019Date of Patent: April 4, 2023Assignee: Vertex Pharmaceuticals IncorporatedInventors: Jingrong Cao, Jon H. Come, Leslie A. Dakin, Francois Denis, Warren A. Dorsch, Anne Fortier, Martine Hamel, Elaine B. Krueger, Brian Ledford, Suganthini S. Nanthakumar, Olivier Nicolas, Camil Sayegh, Timothy J. Senter, Tiansheng Wang, Michael Brodney, Kan-Nian Hu, Peter Rose, Kevin Gagnon, Yi Shi, Muna Shrestha, Ales Medek, Faith Witkos
-
Patent number: 11485739Abstract: The present invention relates to compounds useful as inhibitors of ATR protein kinase. The invention relates to pharmaceutically acceptable compositions comprising the compounds of this invention; methods of treating of various diseases, disorders, and conditions using the compounds of this invention; processes for preparing the compounds of this invention; intermediates for the preparation of the compounds of this invention; and solid forms of the compounds of this invention. The compounds of this invention have formula I-A or I-B: wherein the variables are as defined herein.Type: GrantFiled: August 17, 2020Date of Patent: November 1, 2022Assignee: VERTEX PHARMACEUTICALS INCORPORATEDInventors: Jean-Damien Charrier, Christopher John Davis, Damien Fraysse, Gorka Etxebarria I Jardi, Simon Pegg, Francoise Pierard, Joanne Pinder, John Studley, Carl Zwicker, Tapan Sanghvi, Michael Waldo, Ales Medek, David Matthew Shaw, Maninder Panesar, Yuegang Zhang, Naziha Alem
-
Publication number: 20210308053Abstract: The present invention features compositions comprising a plurality of therapeutic agents wherein the presence of one therapeutic agent enhances the properties of at least one other therapeutic agent. In one embodiment, the therapeutic agents are cystic fibrosis transmembrane conductance regulators (CFTR) such as a CFTR corrector or CFTR potentiator for the treatment of CFTR mediated diseases such as cystic fibrosis. Methods and kits thereof are also disclosed.Type: ApplicationFiled: March 17, 2021Publication date: October 7, 2021Applicant: Vertex Pharmaceuticals IncorporatedInventors: Brian Dean Phenix, Laurent Jean-Claude Bagnol, Geoffrey Glen Brodeur, Sachin Chandran, Eleni Dokou, Lori Ann Ferris, Dragutin Knezic, Katie Lynn McCarty, Ales Medek, Sara A. Waggener
-
Publication number: 20210246121Abstract: The disclosure provides novel solid state forms of Compound I selected from Form B, citric acid cocrystal Form A, piperazine cocrystal Form A, urea cocrystal Form A, nicotinamide cocrystal Form A, nicotinamide cocrystal Form B, aspartame cocrystal Form A, glutaric acid cocrystal Form A, L-proline cocrystal Form A, L-proline cocrystal Form B, vanillin cocrystal Form A, and 2-pyridone cocrystal Form A, compositions comprising the same, and methods of using the same, including use in treating APOL1 mediated kidney disease.Type: ApplicationFiled: February 3, 2021Publication date: August 12, 2021Inventors: Mei-Hsiu LAI, Jicong LI, Muna SHRESTHA, Ales MEDEK, Yi SHI, Andrey PERESYPKIN, Michael JUDELSON, Jack MINCHOM, Courtney MAGUIRE, Kevin GAGNON, Faith WITKOS, Satish Kumar IYEMPERUMAL, Kanika SARPAL
-
Publication number: 20210179587Abstract: Novel compounds, compositions, and methods of using and preparing the same, which may be useful for treating alpha-1 antitrypsin deficiency (AATD).Type: ApplicationFiled: October 4, 2019Publication date: June 17, 2021Inventors: Upul Keerthi BANDARAGE, Cavan McKeon BLIGH, Michael John BOYD, Diane M. BOUCHER, Michael Aaron BRODNEY, Veronique DAMAGNEZ, Lev Tyler DEWEY FANNING, Mary Elizabeth ECCLES, Robert Francis FIMOGNARI, JR., Kevin James GAGNON, Pedro M. GARCIA BARRANTES, Simon GIROUX, Ronald Lee GREY, JR., Amy Beth HALL, Sarah Carol HOOD, Dennis James HURLEY, Joshua Kennedy HUSSEY, Mac Arthur JOHNSON, JR., Peter JONES, Sarathy KESAVAN, Adam LOOKER, Brad D. MAXWELL, John Patrick MAXWELL, Ales MEDEK, Mettachit NAVAMAL, Philippe Marcel NUHANT, Setu RODAY, Stefanie ROEPER, Rupa SAWANT, Yi SHI, Rebecca Jane SWETT, Qing TANG, Timothy Lewis TAPLEY, Stephen A. THOMSON, Michael WALDO, Jinwang XU
-
Patent number: 10980746Abstract: The present invention features compositions comprising a plurality of therapeutic agents wherein the presence of one therapeutic agent enhances the properties of at least one other therapeutic agent. In one embodiment, the therapeutic agents are cystic fibrosis transmembrane conductance regulators (CFTR) such as a CFTR corrector or CFTR potentiator for the treatment of CFTR mediated diseases such as cystic fibrosis. Methods and kits thereof are also disclosed.Type: GrantFiled: December 26, 2018Date of Patent: April 20, 2021Assignee: Vertex Pharmaceuticals IncorporatedInventors: Brian Dean Phenix, Laurent Jean-Claude Bagnol, Geoffrey Glen Brodeur, Sachin Chandran, Eleni Dokou, Lori Ann Ferris, Dragutin Knezic, Katie Lynn McCarty, Ales Medek, Sara A. Waggener
-
Publication number: 20210047323Abstract: Crystalline forms of Compound I: pharmaceutically acceptable salts thereof, and solvates and hydrates thereof are disclosed. Pharmaceutical compositions comprising the same, methods of treating cystic fibrosis using the same, and methods for making the same are also disclosed.Type: ApplicationFiled: August 13, 2020Publication date: February 18, 2021Inventors: Yi Shi, Kevin J. Gagnon, Jicong Li, Jennifer Lu, Ales Medek, Muna Shrestha, Michael Waldo, Beili Zhang, Carl L. Zwicker, Corey Don Anderson, Jeremy J. Clemens, Thomas Cleveland, Timothy Richard Coon, Bryan Frieman, Peter Grootenhuis, Sara Sabina Hadida Ruah, Jason McCartney, Mark Thomas Miller, Prasuna Paraselli, Fabrice Pierre, Sara E. Swift, Jinglan Zhou
-
Publication number: 20210032255Abstract: The present invention relates to compounds useful as inhibitors of ATR protein kinase. The invention relates to pharmaceutically acceptable compositions comprising the compounds of this invention; methods of treating of various diseases, disorders, and conditions using the compounds of this invention; processes for preparing the compounds of this invention; intermediates for the preparation of the compounds of this invention; and solid forms of the compounds of this invention. The compounds of this invention have formula I-A or I-B: wherein the variables are as defined herein.Type: ApplicationFiled: August 17, 2020Publication date: February 4, 2021Inventors: Jean-Damien CHARRIER, Christopher John DAVIS, Damien FRAYSSE, Gorka ETXEBARRIA I JARDI, Simon PEGG, Francoise PIERARD, Joanne PINDER, John STUDLEY, Carl ZWICKER, Tapan SANGHVI, Michael WALDO, Ales MEDEK, David Matthew SHAW, Maninder PANESAR, Yuegang ZHANG, Naziha ALEM
-
Publication number: 20200377479Abstract: The disclosure provides at least one entity chosen from compounds of formula (I), solid state forms of the same, compositions comprising the same, and methods of using the same, including use in treating focal segmental glomeulosclerosis (FSGS) and/or non-diabetic kidney disease (NDKD).Type: ApplicationFiled: December 17, 2019Publication date: December 3, 2020Inventors: Jingrong CAO, Jon H. COME, Leslie A. DAKIN, Francois DENIS, Warren A. DORSCH, Anne FORTIER, Martine HAMEL, Elaine B. KRUEGER, Brian LEDFORD, Suganthini S. NANTHAKUMAR, Olivier NICOLAS, Camil SAYEGH, Timothy J. SENTER, Tiansheng WANG, Michael BRODNEY, Kan-Nian HU, Peter Rose, Kevin GAGNON, Yi SHI, Muna SHRESTHA, Ales MEDEK, Faith WITKOS
-
Publication number: 20200361939Abstract: The disclosure provides compounds useful for treating alpha-1 antitrypsin deficiency (AATD), according to formula (I): tautomers thereof, pharmaceutically acceptable salts of the compounds, pharmaceutically acceptable salts of the tautomers, deuterated derivatives of the compounds, deuterated derivatives of the tautomers, and deuterated derivatives of the salts, solid forms of those compounds and processes for making those compounds.Type: ApplicationFiled: May 13, 2020Publication date: November 19, 2020Inventors: Upul Keerthi BANDARAGE, Cavan McKeon BLIGH, Diane BOUCHER, Michael John BOYD, Michael Aaron BRODNEY, Michael Philip CLARK, Veronique DAMAGNEZ, Lev Tyler Dewey FANNING, Robert Francis FIMOGNARI, Gabrielle Simone FLEMING, Kevin James GAGNON, Pedro Manuel GARCIA BARRANTES, Robert Daniel GIACOMETTI, Simon GIROUX, Ronald Lee GREY, Jr., Samantha GUIDO, Amy Beth HALL, Sarah Carol HOOD, Dennis James HURLEY, Mac Arthur JOHNSON, Jr., Peter Jones, Sarathy KESAVAN, Mei-Hsiu LAI, Siying LIU, Adam LOOKER, Brad MAXWELL, John Patrick MAXWELL, Ales MEDEK, Philippe Marcel NUHANT, Kirk Alan OVERHOFF, Setu RODAY, Stefanie ROEPER, Steven M. RONKIN, Rupa SAWANT, Yi SHI, Muna SHRESTHA, Marisa SPOSATO, Kathy STAVROPOULOS, Rebecca Jane SWETT, Timothy Lewis TAPLEY, Qing TANG, Stephen THOMSON, Jinwang XU, Mariam ZAKY
